Dose-related statin myopathy: Is it an issue?

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 9, 2005, Pages 751-756

  Worthmann, Robert L ^a  

^a University of Oklahoma Tulsa College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; NICOTINIC ACID; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; SELENOPROTEIN; UBIDECARENONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; FATIGUE; HUMAN; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

EID: 25844507166     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.9.751     Document Type: Editorial

References (29)

1. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
3. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
4. Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106:1024-1028.
5. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
6. Jones PHJ. The benefits of individualized starting doses in statin therapy. Cleve Clin J Med 2005; 72:811-816.
7. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
8. La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:425-435.
9. Bradford RH, Shear CL, Chemos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151:43-49.
10. Gaist D, Rodriguez LAG, Huerta C, et al. Lipid-lowering drugs and the risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12:565-569.
11. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358:1383-1385.
12. Downs JR, Clearfield M, Tyoler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87:1074-1079.
13. Thompson P, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.
14. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585-2590.
15. Cholesterol statistics. American Heart Association. Available at www.americanheart.org. Accessed April 2005.
16. Baker SK, Tarpolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001; 24:2258-2272.
17. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Ther 1998; 15:218-228.
18. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46:1055-1057.
19. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994; 24:171-176.
20. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851-854.
21. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269:1270-1272.
22. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004; 363:892-894.
23. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal and abnormal creatine kinase: clinical, pathological and biochemical features. Ann Intern Med 2002; 137:581-585.
24. Vladutiu G, Isaackson P, Wortmann R. Metabolic disorders and cholesterol-lowering drugs [abstract). Arthritis Rheum 2004; 50(suppl):S667.
25. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2002; 27:142-156.
26. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25:649-663.
27. Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002; 14:643-647.
28. Hung YT, Yeung VTF. Hypothyroidism presenting as hypercholesterolemia and simvastatin-induced myositis. Hong Kong Med J 2000; 6:423-424.
29. Shults CW, Shapira AHV. A cue to queue for CoQ? Neurology 2001; 57:375-376.